Modifications of immunity in obesity: The impact on the risk of infection;Modifications de l'immunité dans l'obésité: Impact sur le risque infectieux

Revue de Medecine Interne

Volumn 36, Issue 11, 2015, Pages 760-768

  Meckenstock, R ^a   Therby, A ^a  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

Immunity; Infection; Obesity

Indexed keywords

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; HUMAN; IMMUNE RESPONSE; IMMUNITY; INCIDENCE; INFECTION; INFECTION RISK; METABOLIC DISORDER; NEOPLASM; OBESITY; PUBLIC HEALTH PROBLEM; RISK FACTOR; SHORT SURVEY; IMMUNE SYSTEM; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY;

CYTOKINE;

ADIPOSE TISSUE; CYTOKINES; HUMANS; IMMUNE SYSTEM; INFECTION; INFLAMMATION; OBESITY;

EID: 84945291075     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2015.07.013     Document Type: Short Survey

References (93)

1. Morrill A.C., Chinn C.D. The obesity epidemic in the United States. J Public Health Policy 2004, 25:353-366.
2. ObEpi Enquête nationale épidémiologique sur le surpoids et l'obésité 2012, INSERM/KANTAR HEALTH/ROCHE.
3. Organisation mondiale de la santé. Obésité et surpoids. Aide mémoire no 113. [Accès au site le 3/3/2014]. http://www.who.int/mediacentre/factsheets/fs311/fr.
4. Karlsson E.A., Beck M.A. The burden of obesity on infectious disease. Exp Biol Med 2010, 235:1412-1424.
5. Basdevant A. Origine des obésités. Médecine de l'obésité 2009, 33-45. Médecine Sciences Flammarion, Paris. A. Basdevant, B. Guy-Grand (Eds.).
6. Lubrano-Berthelier C., Clement K. Génétique de l'obésité humaine. Rev Med Interne 2005, 26:802-811.
7. Bouchard C. Current understanding of the aetiology of obesity: genetic and non-genetic factors. Am J Clin Nutr 1991, 53. 1561-65S.
8. Pi-Sunyer F.X. The obesity epidemic: pathophysiology and consequences of obesity. Obesity Res 2001, 10. 97S-104S.
9. Pi-Sunyer F.X. The medical risks of obesity. Obes Surg 2002, 12:6-11.
10. Sjostrom L. Morbidity of severely obese subjects. Am J Clin Nutr 1992, 55. 508-15S.
11. er janvier 2013 2014, [Accès au site le 3/3/2014]. http://www.e-cancer.fr/publications/75-prevention/652-surpoids-obesite-et-risque-de-cancers.
12. Lynch L.A., O'Connell J.M., Kwasnik A.K., Cawood T.J., O'Farrelly C., O'Shea D.B. Are natural killer cells protecting the metabolically healthy obese patient?. Obesity 2009, 17:601-605.
13. O'Shea D., Cawood D.J., O'Farrelly C., Lynch L. Natural killer cells in obesity: impaired function and increased susceptibility to the effects of cigarette smoke. PLoS ONE 2010, 5:e8660.
14. Anaya D.A., Dellinger E.P. The obese surgical patient: a susceptible host for infection. Surg Infect 2006, 7:473-480.
15. Falagas M.E., Kompoti M. Obesity and infection. Lancet Infect Dis 2006, 6:438-446.
16. Canturk Z., Canturk N.Z., Cetinarslan B., Utkan N.Z., Tarkun I. Nosocomial infections and obesity in surgical patients. Obesity Res 2003, 11:769-775.
17. Doyle S.L., Lysaght J., Reynolds J.V. Obesity and post-operative complications in patients undergoing non-bariatric surgery. Obes Rev 2009, 11:875-876.
18. Calle E.E., Thun M.J., Petrelli J.M., Rodriguez C., Heath C.W. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999, 341:1097-1105.
19. Choban P.S., Heckler R. Increased incidence of nosocomial infections in obese surgical patients. Am Surg 1995, 61:1001.
20. Choban P.S., Flancbaum L. The impact of obesity on surgical outcomes: a review. Am Surg 1995, 61:1001.
21. Finucane O.M., Reynolds C.M., McGillicuddy F.C., Roche H.M. Insights into the role of macrophage migration inhibiting factor in obesity and insulin resistance. Proc Nutr Soc 2012, 22:1-12.
22. Flegal K.M., Graubard B.I., Williamson D.F., et al. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007, 298:2028-2037.
23. Arslan E., Atllgan H., Yavasoglu I. The prevalence of Helicobacter pylori in obese subjects. Eur J Int Med 2009, 103:1830-1835.
24. Uberos J., Molina-Carballo A., Fernendez-Puentes V., Rodriguez-Belmonte R., Muaz-Hoyos A. Overweight and obesity as risk factors for the asymptomatic carrier state of Neisseria meningitides among a pediatric population. Eur J Clin Microbiol Infect Dis 2010, 29:333-334.
25. Fezeu L., Julia C., Henegar A., Hu F.B., Grobbee D.E., Kengne A.P., et al. Obesity is associated with higher risk of intense care unit admission and death in influenza A (H1N1) patients: a systematic review and meta-analysis. Obes Rev 2011, 12:653-659.
26. Choban P.S., Heckler R., Burge J.C., Flancbaum L. Increased incidence of nosocomial infections in obese surgical patients. Am Surg 1995, 61:1001-1005.
27. Sagi H.C., Dziadosz D., Mir H., Virani N., Olson C. Obesity, leucocytosis, embolization, and injury severity increase the risk for deep postoperative wound infection after pelvic and acetabular surgery. J Orthop Trauma 2013, 27:6-10.
28. Podnos Y.D., Jimenez J.C., Wilson S.E., Stevens C.M., Ngyuen N.T. Complications after laparoscopic gastric bypass: a review of 3463 cases. Arch Surg 2003, 138:957-961.
29. Koziolek M., Krzyzanowska-Swiniarska B., Maczynska I., Miazgowski T., Giedrys-Kalemba S. The association between past chlamydia pneumonia infection and markers of chronic inflammation in obese women. Eur J Clin Microbiol Infect Dis 2008, 27:415-421.
30. Hinnouho G.M., Czernichow S., Dugravot A., Batty G.D., Kivimaki M., Singh-Manour A. Metabolically healthy obesity and risk of mortality. Diabetes Care 2013, 36:2294-2300.
31. Appleton S.L., Seaborn C.J., Visvanathan R., Hill C.L., Gill T.K., Taylor A.W., et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype. Diabetes Care 2013, 36:2388-2394.
32. Kleemann R., Bucala R. Macrophage migration factor: critical role in obesity, insulin resistance, and associated comorbidities. Mediators Inflamm 2010, 10.1155/2010/610479.
33. Gaillard RC. Le tissu adipeux: un véritable organe endocrine. [Accès au site le 3/3/2014]. http://ww.revmed.ch/rms/2003/RMS-2424/22822.
34. Poitou C, Clément K. Le tissu adipeux: un acteur majeur du syndrome inflammatoire de l'obésité ? [Accès au site le 3/3/2014]. http://www.em-consulte.com/en/article/79212.
35. Wozniak S.E., Gee L.L., Wachtel M.S., Frezza E.E. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009, 54:1847-1856.
36. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direst role in obesity-linked insulin resistance. Science 1993, 259(5091):87-91.
37. Poitou C., Dalmas E., Clément K. Physiologie et physiopathologie du tissu adipeux. Physiologie et physiopathologie du tissu adipeux 2013, 289-301. Lavoisier, Paris. J.P. Bastard, B. Fève (Eds.).
38. Hotamisligil G.S., Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 2008, 8:923-934.
39. Galgani M., Matarese G. Editorial: acute inflammation in obesity: IL-17A in the middle of the battle. J Leuk Biol 2010, 87:17-18.
40. Yang H., Youm Y.H., Vandanmagsar B., Rood J., Kumar K.G., Butler A.A., et al. Obesity accelerates thymic aging. Blood 2009, 29:3803-3812.
41. Undurti N. Obesity and its relationship to coronary heart disease. Eur Heart J 2007, [Accès au site le 3/3/2014]. 10.1093/eurheartj/ehm472.
42. Bracho-Riquelme R.L., Reyes-Romero M.A., Pescador N., Flores-García A.I. A leptin serum concentration less than 10ng/ml is a predictive marker of outcome in patients with moderate to severe secondary peritonitis. Eur Surg Res 2008, 41(2):238-244.
43. Procaccini C., Lourenco E.V., Matarese M., La Cava A. Leptin signaling: a key pathway in immune responses. Curr Signal Transduct Ther 2009, 4:22-30.
44. La Cava A.L., Matarese G. The weight of leptine in immunity. Nat Rev 2004, 4:371-379.
45. Dorner T.E., Schwarz F., Kranz A., Freidl W., Rieder A., Gisinger C. Body mass index and the risk of infections in institutionalized geriatric patients. Br J Nutr 2010, 103:1830-1835.
46. Hill R.A., Margetic S., Pegg G.G., Gazzola C. Leptin: its pharmacokinetics and tissue distribution. Int J Obes Relat Metab Disord 1998, 22:765-770.
47. Torpy D.J., Bornstein S.R., Chrousos G.P. Leptin and interleukin-6 in sepsis. Horm Metab Res 1998, 30:726-729.
48. Nieman D.C., Henson D.A., Nehlsen-Cannarella S.L., Ekkens M., Utter A.C., Butterworth D.E., et al. Influence of obesity on immune function. J Am Diet Assoc 1999, 99:294-299.
49. Burgos Ramos E., Canelles S., Perianes-Cachero A., Arilla-Ferreiro E., Argente J., Barrios V. Adipose tissu promotes a serum cytokine profile related to lower insulin sensitivity after chronic central leptin infusion. PLoS One 2012, 7(10):e46893.
50. Tschop J., Nogueiras R., Haas-Lockie S., Kasten K.R., Castaneda T.R., Huber N., et al. CNS leptin action modulates immune response and survival in sepsis. J Neurosci 2010, 30:6036-6047.
51. Flier J.S. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004, 116:337-350.
52. Farooqi I.S., Matarese G., Lord G.M., Keogh J.M., Lawrence E., Agwu C., et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroencrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002, 110:1093-1103.
53. Wrann C.D., Laue T., Hübner L., Kuhlmann S., Jacobs R., Goudeva L., et al. Short-term and long-term leptin exposure differentially affect human natural killer cell immune functions. Am J Physiol Endocrinol Metab 2012, 302:108-116.
54. Koch A., Weiskirchen R., Zimmermann H.W., Sanson E., Trautwein C., Tacke F. Relevance of serum leptin and leptin-receptor concentrations in critically ill patients. Mediators Inflamm 2010, 10.1155/2010/473540.
55. Esteghamati A., Noshad S., Khalilzadeh O., Morteza A., Nazeri A., Meysamie A., et al. Contribution of serum leptin to metabolic syndrome in obese and anobese subjects. Arch Med Res 2011, 42:244-251.
56. Peake P.W., Kriketos A.D., Campbell L.V., Shen Y., Charlesworth J.A. The metabolism of isoforms of human adiponectin: studies in human subjects and in experimental animals. Eur J Endocrinol 2005, 153:409-417.
57. Yokota T., Oritani K., Takahashi I., Ishikawa J., Matsuyama A., Ouchi N., et al. Adiponectine, a new member of the family of soluble defence collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96:1723-1732.
58. Tsatsanis C., Margioris A.N., Kontoyiannis D.P. Association between H1N1 infection severity and obesity - adiponectin as a potential etiologic factor. JID 2010, 202:459-460.
59. Grieb G., Merk M., Bernhagen J., Buccala R. Macrophage migration inhibiting factor (MIF): a promising biomarker. Drug News Perspect 2010, 23:257-264.
60. Juge-Aubry C.E., Henrichot E., Meier C.A. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab 2005, 19:547-566.
61. Tanaka S.I., Isoda F., Ishihara Y., Kimura M., Yamakawa T. T lymphopenia in relation to body mass index and TNF-alpha in human obesity: adequate weight reduction can be corrective. Clin Endocrinol 2001, 54:347-354.
62. O'Rourke R.W., Kay T., Scholz M.H., Diggs B., Jobe B.A., Lewinsohn D.M., et al. Alterations in T-cell subset frequency in peripheral blood in obesity. Obes Surg 2005, 15:1463-1468.
63. Nieman D.C., Nehlsen-Cannarella S.I., Henson D.A., Butterworth D.E., Fagoaga O.R., Warren B.J., et al. Immune response to obesity and moderate weight loss. Int J Obes Relat Metab Disord 1996, 20:353-360.
64. Morgan O.W., Bramley A., Fowlkes A., Freedman D.S., Taylor T.H., Gargiullo P., et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 panendemic influenza A (H1N1) disease. PLoS ONE 2012, 5:e9694.
65. Kamchybekov U., Figulla H.R., Gerdes N., Jung C. Macrophage migration inhibiting factor is elevated in obeseadolescents. Arch Physiol Biochem 2012, 118:204-209.
66. Dandona P., Aljada A., Ghanim H., Mohanty P., Tripathy C., Hofmeyer D., et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. JCEM 2004, 89:5043-5047.
67. Eder K., Baffy N., Falus A., Fulop A.K. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res 2009, 58:727-736.
68. Lamas O., Marti A., Martinez J.A. Obesity and immunocompetence. Eur J Clin Nutr 2002, 56 Suppl.(3):42-45.
69. El-Wakkad A., Hassan N.E., Sibaii H., El-Zayat S.R. Proinflammatory, anti-inflammatory cytokines and adipokines in students with central obesity. Cytokine 2013, 61:682-687.
70. Kern P.A., Ranganathan S., Li C., Wood L., Ranganathan L. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001, 280:E745-E751.
71. Janneway C.A., Murphy K., Travers P., Walport M. Immunobiologie 2009, Éditions de Boeck université, 349-51 et 426-32. 3e édition.
72. Tan L., Gozal D., Yang W., Hari P., Bandla P.R., Bhattacharjee R., et al. Alterations in circulating T-cell lymphocyte populations in children with obstructive sleep apnoea. SLEEP 2013, 36. 913-922A.
73. Ye J., Liu H., Zhang G., Li P., Huang S., Yang Q., et al. The Treg/Th17 imbalance in patients with obstructive sleep apnoea. Mediators Inflamm 2012, 10.1155/2012/815308.
74. Abrams B. Long-term sleep apnea as a pathogenic factor for cell-mediated autoimmune disease. Med Hypotheses 2005, 65:1024-1027.
75. Dyugovskaya L., Lavie P., Hirsh M., Lavie L. Activated CD8+ lymphocytes in obstructive sleep apnoea. Eur Respir J 2005, 25:820-828.
76. Fabbrini E., Cella M., McCartney S.A., Fuchs A., Abumrad N.A., Pietka C.A., et al. Association between speficic adipose tissu CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology 2013, 145:36-74.
77. Svec P., Vásárhelyi B., Pástzthy B., Körner A., Kovács L., Tulassau T., et al. Do regulatory T cells contribute to Th1 skewness in obesity?. Exp Clin Endocrinol Diabetes 2007, 115:439-443.
78. Bouanane S, Merzouk H, Baba Ahmed FZ, Saker, Mokhtari N, Benkalfat et al. La lymphoprolifération et la sécrétion des interleukines des enfants obèses. [Accès au site le 3/3/2014]. http://slideshare.net/JIBBiology/poster-85-immunologie.
79. Weber D.J., Rutal W.A., Samsa G.P., Santimaw J.E., Lemon S.M. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 1985, 254:3187-3189.
80. Waterhouse D.F., Cahill R.A., Sheehan F., McCreery C. Prediction of calculated future cardiovascular disease by monocyte count in an asymptomatic population. Vasc Health Risk Manag 2008, 4:177-187.
81. Poitou C., Dalmas E., Renovato M., Benhamo V., Hajduch F., Abdennour M., et al. CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2011, 31:2322-2330.
82. Engel A., Kern W.V., Mürdter G., Kern P. Kinetics and correlation with body temperature of circulating interleukin-6, interleukin-8, tumor necrosis factor alpha and interleukin-1 beta in patients with fever and neutropenia. Infection 1994, 22:160-164.
83. Chung D.R., Lee Y.S., Lee S.S. Kinetics of inflammatory cytokines in patients with scrub typhus receiving doxycycline treatment. J Infect 2008, 6:44-50.
84. Jekarl D.W., Lee S.Y., Lee J., Park Y.J., Kim Y., Park J.H., et al. Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis. Diagn Microbiol Inf Dis 2013, 75:342-347.
85. Shapiro N.I., Khankin E.V., van Meurs M., Shih S.C., Lu S., Yano M., et al. Leptin exacerbates sepsis-mediated morbidity and mortality. J Immunol 2010, 185:517-524.
86. Hillenbrand A., Knippschild U., Weiss M., Schrezenmeier H., Henne-Bruns D., Huber-Lang M., et al. Sepsis induced changes of adipokines and cytokines - septic patients compared to morbidly obese patients. BMC Surg 2010, 10:26.
87. Diez M.L., Santolaria F., Tejera A., Alemán M.R., Gonzáles-Reimers E., Milena A., et al. Serum leptin levels in community acquired pneumonia (CAP) are related to nutritional status and not to acute phase reaction. Cytokine 2008, 42:156-160.
88. Behnes M., Brueckmann M., Lang S., Putensen C., Saur J., Borggrefe M., et al. Alterations of leptin in the course of inflammation and severe sepsis. BMC Infec Dis 2012, 12:217.
89. Langouche L., van der Perre S., Frystyk J., Flyvbjerg A., Hansen T.K., van der Berghe G. Adiponectin, retinol-binding protein 4, and leptin in protracted critical illness of pulmonary origin. Crit Care 2009, 13:R112.
90. Venkatesh B., Hickman I., Nisbet J., Cohen J., Prins J. Changes in serum adiponectin concentrations in critical illness: a preliminary investigation. Crit Care 2009, 13:R105.
91. Hillenbrand A., Weiss M., Knippschild U., Strohmeyer H.G., Henne-Bruns D., Huber-Lang M., et al. Association of adiponectin levels and insulin demand in critically ill patients. Diabetes Metab Syndr Obes 2011, 4:45-51.
92. Illan Gomez F., Gonzalvez-Ortega M., Orea-Soler I., Alcaraz-Tafalla M.S., Aragon-Alonso A., et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumor necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg 2012, 22:950-955.
93. Bruunsgaard 2012 H Physical activity and modulation of systemic low-level inflammation. J Leucocyte Biol 2005, 78:819-835.